{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:21:18Z","timestamp":1777922478796,"version":"3.51.4"},"reference-count":53,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Monoclonal Antibodies in Immunodiagnosis &amp; Immunotherapy"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:p>\n                    The CC chemokine receptor type-4 (CCR4) belongs to the G-protein-coupled receptor superfamily, expressed on the cell surface of T cells and its malignancy. Two CCR4 ligands (CCL17 and CCL22) bind to CCR4 that mediate physiological and pathological functions of T cell immune responses. Anti-CCR4 monoclonal antibody (mAb) mogamulizumab is approved for adult T cell leukemia\/lymphoma and cutaneous T cell lymphomas. In addition, mogamulizumab can deplete regulatory T cells, implying the application to solid tumors as an immunomodulator. Therefore, the development of sensitive mAbs for CCR4 has been desired for basic research, diagnosis, and therapy. In this study, a specific, and sensitive anti-mouse CCR4 (mCCR4) mAb, C\n                    <jats:sub>4<\/jats:sub>\n                    Mab-1 (rat IgG\n                    <jats:sub>1<\/jats:sub>\n                    , kappa), was established using N-terminal peptide immunization. C\n                    <jats:sub>4<\/jats:sub>\n                    Mab-1 reacted with mCCR4-overexpressed Chinese hamster ovary (CHO)-K1 cells, P388 (mouse lymphoid neoplasm), and J774-1 (mouse macrophage-like) cells in flow cytometry. Kinetic analyses using flow cytometry showed that\n                    <jats:italic toggle=\"yes\">K<\/jats:italic>\n                    <jats:sub>D<\/jats:sub>\n                    s of C\n                    <jats:sub>4<\/jats:sub>\n                    Mab-1 for CHO\/mCCR4, P388, and J774-1 cells were 4.2\u2009\u00d7\u200910\n                    <jats:sup>\u22129<\/jats:sup>\n                    M, 5.4\u2009\u00d7\u200910\n                    <jats:sup>\u22127<\/jats:sup>\n                    M, and 1.1\u2009\u00d7\u200910\n                    <jats:sup>\u22126<\/jats:sup>\n                    M, respectively. C\n                    <jats:sub>4<\/jats:sub>\n                    Mab-1 could be a valuable tool for elucidating mCCR4-related biological responses.\n                  <\/jats:p>","DOI":"10.1089\/mab.2021.0064","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T14:49:38Z","timestamp":1650984578000},"page":"87-93","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Development of a Novel Anti-Mouse CCR4 Monoclonal Antibody (C\n                    <sub>4<\/sub>\n                    Mab-1) by N-Terminal Peptide Immunization"],"prefix":"10.1177","volume":"41","author":[{"given":"Junko","family":"Takei","sequence":"first","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teizo","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika K.","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5385-8201","authenticated-orcid":false,"given":"Yukinari","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan."},{"name":"Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215542"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.120.000011"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.126079"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxf044"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxu079"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12440"},{"key":"e_1_3_3_8_2","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: Its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida T","year":"2003","unstructured":"Ishida T, , Utsunomiya A, , Iida S, , Inagaki H, , Takatsuka Y, , Kusumoto S, , Takeuchi G, , Shimizu S, , Ito M, , Komatsu H, , Wakita A, , Eimoto T, , Matsushima K, , and Ueda R: Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: Its close association with skin involvement and unfavorable outcome. Clin Cancer Res, 2003; 9:3625\u20133634.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.685.014k26_685_690"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2006.00307.x"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M210665200"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/11631090-000000000-00000"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3472"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0830"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-600924"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13357"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30449-2"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201847659"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1090"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0357"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2020.0003"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11753"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2020.0015"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2018.03.007"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2017.0031"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.12246"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.3892\/or.2020.7808"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.3892\/or.2021.8124"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2021.0008"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2021.0006"},{"key":"e_1_3_3_32_2","first-page":"23","article-title":"Development and characterization of TrMab6, a novel antiTROP2 monoclonal antibody for antigen detection in breast cancer","author":"Sayama Y","year":"2021","unstructured":"Sayama Y, , Kaneko MK, , and Kato Y: Development and characterization of TrMab6, a novel antiTROP2 monoclonal antibody for antigen detection in breast cancer. Mol Med Rep, 2021; 23.","journal-title":"Mol Med Rep"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2020.100902"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2018.0004"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2021.0015"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2021.0011"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2020.0005"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2019.0013"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2019.100644"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2019.100631"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2019.100633"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2019.e02063"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2018.0048"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2019.01.009"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2019.0003"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2021.0009"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2021.0005"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2021.0007"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2015.105"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2697"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2002.19610.x"},{"key":"e_1_3_3_52_2","first-page":"1949","article-title":"A defucosylated antiCD44 monoclonal antibody 5mG2af exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma","volume":"44","author":"Takei J","year":"2020","unstructured":"Takei J, , Kaneko MK, , Ohishi T, , Hosono H, , Nakamura T, , Yanaka M, , Sano M, , Asano T, , Sayama Y, , Kawada M, , Harada H, , and Kato Y: A defucosylated antiCD44 monoclonal antibody 5mG2af exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma. Oncol Rep, 2020; 44:1949\u20131960.","journal-title":"Oncol Rep"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25132"},{"key":"e_1_3_3_54_2","first-page":"1443","article-title":"AntiEGFR monoclonal antibody 134mG2a exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma","volume":"46","author":"Hosono H","year":"2020","unstructured":"Hosono H, , Takei J, , Ohishi T, , Sano M, , Asano T, , Sayama Y, , Nakamura T, , Yanaka M, , Kawada M, , Harada H, , Kaneko MK, , and Kato Y: AntiEGFR monoclonal antibody 134mG2a exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma. Int J Mol Med, 2020; 46:1443\u20131452.","journal-title":"Int J Mol Med"}],"container-title":["Monoclonal Antibodies in Immunodiagnosis &amp; Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mab.2021.0064","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mab.2021.0064","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mab.2021.0064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:21:46Z","timestamp":1777666906000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mab.2021.0064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1089\/mab.2021.0064"],"URL":"https:\/\/doi.org\/10.1089\/mab.2021.0064","relation":{},"ISSN":["2167-9436","2167-9436"],"issn-type":[{"value":"2167-9436","type":"print"},{"value":"2167-9436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}